Niagen Bioscience, Inc. — Director's Dealing 2012

Feb 24, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ChromaDex Corp. (CDXC.OB)
CIK: 0001386570
Period of Report: 2012-02-23

Reporting Person: Himmel Jeffrey (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-02-23	Common Stock, Par Value $0.001 per share	P	1000000	$0.00	Acquired	2433333	Direct

Footnotes

F1: The shares were purchased pursuant to the Securities Purchase Agreement dated February 23, 2012, and will vest in full on February 1, 2015, provided that a certain stock performance condition is met.